Pharmaceutical Executive-09-01-2020

In this September 2020 Product Launch issue of Pharm Exec, we highlight five products, all approved in 2019, and showcase what is now their early brand journey.

Beyond necessity and nice-to-have, embracing real-world evidence as a true strategic differentiator.

Turning to a next-gen psoriasis treatment to help drive future fortunes.

While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.

Uncovering fish oil derivative’s benefit for heart health.

New hope accompanies overdue recognition in sickle cell disease fight.

Addressing the need for fast-acting therapy in treatment-resistant depression.

The world’s most expensive drug put in context.

The key factors behind the sector’s strong surge in new equity fundraisings.

Orphan drug incentives set to remain in place in Europe.

Tasked with setting up framework for essential medicine program.

How adoption of the key account management (KAM) model can help drive pharma’s agility in reaching and influencing a more diverse set of healthcare customers and decision-makers.

As we wait for a COVID-19 vaccine, pharma is looking to blockchain technology to prepare for the major supply-chain obstacles to come.

Creating behavioral change in the pharma workplace.

Amid pandemic, rely on the fundamentals.

A glimpse inside the latest turn in Liz Barrett’s influential journey as an oncology executive—this time leaving the confines of big pharma to tackle the innovation void in treating urologic cancers.

ESG objectives are integral to long-term biopharma strategy.

Assessing COVID-19’s wide and varied impact on pharma and biotech business in the first half of the year, and how it shapes market prospects ahead.

Click the title above for a link to open the Pharmaceutical Executive September 2020 issue in an interactive PDF format.